Literature DB >> 26924193

DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.

Iris H Liu1, James M Ford2, Pamela L Kunz3.   

Abstract

BACKGROUND: The role of DNA repair in pathogenesis and response to treatment is not well understood in pancreatic neuroendocrine tumors (pNETs). However, the existing literature reveals important preliminary trends and targets in the genetic landscape of pNETs. Notably, pNETs have been shown to harbor defects in the direct reversal MGMT gene and the DNA mismatch repair genes, suggesting that these genes may be strong candidates for further prospective studies.
METHODS: PubMed searches were conducted for original studies assessing the DNA repair genes MGMT and MMR in pNETs, as well as for PTEN and MEN1, which are not directly DNA repair genes but are involved in DNA repair pathways. Searches were specific to pNETs, yielding five original studies on MGMT and four on MMR. Six original papers studied PTEN in pNETs. Five studied MEN1 in pNETs, and two others implicated MEN1 in DNA repair processes.
RESULTS: The five studies on MGMT in pNET tumor samples found MGMT loss of between 24% and 51% of tumor samples by IHC staining and between 0% and 40% by promoter hypermethylation, revealing discrepancies in methods assessing MGMT expression as well as potential weaknesses in the correlation between MGMT IHC expression and promoter hypermethylation rates. Four studies on MMR in pNET tumor samples indicated similar ambiguities, as promoter hypermethylation of the MLH1 MMR gene ranged from 0% to 31% of pNETs, while IHC staining revealed loss of MMR genes in between 0% and 36% of pNETs sampled. Studies also indicated that PTEN and MEN1 are commonly mutated or underexpressed genes in pNETs, although frequency of mutation or loss of expression was again variable among different studies.
CONCLUSION: Further studies are essential in determining a more thorough repertoire of DNA repair defects in pNETs and the clinical significance of these defects. This literature review synthesises the existing knowledge of relevant DNA repair pathways and studies of the specific genes that carry out these repair mechanisms in pNETs.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Carcinoid; DNA repair; MGMT; MMR; Neuroendocrine tumor

Mesh:

Substances:

Year:  2015        PMID: 26924193     DOI: 10.1016/j.ctrv.2015.11.006

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  4 in total

1.  Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms.

Authors:  Anna Koumarianou; Gregory A Kaltsas; Eleftherios Chatzellis; Georgios Kyriakopoulos; Denise Kolomodi; Krystallenia I Alexandraki
Journal:  Endocrine       Date:  2021-02-05       Impact factor: 3.633

2.  Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice.

Authors:  Eugenia Y Xu; Evan Vosburgh; Chung Wong; Laura H Tang; Daniel A Notterman
Journal:  Oncotarget       Date:  2020-07-14

3.  Two well-differentiated pancreatic neuroendocrine tumor mouse models.

Authors:  Chung Wong; Laura H Tang; Christian Davidson; Evan Vosburgh; Wenjin Chen; David J Foran; Daniel A Notterman; Arnold J Levine; Eugenia Y Xu
Journal:  Cell Death Differ       Date:  2019-06-03       Impact factor: 15.828

4.  The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy.

Authors:  Bo Yang; Bin Zhang; Zhifei Cao; Xingdong Xu; Zihe Huo; Pan Zhang; Shufen Xiang; Zhe Zhao; Chunping Lv; Mei Meng; Gaochuan Zhang; Liang Dong; Shucheng Shi; Lan Yang; Quansheng Zhou
Journal:  Cell Death Differ       Date:  2020-03-06       Impact factor: 15.828

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.